What a desert lizard teaches us about patents and the GLP-1 revolution

Gallup data cited in the article show U.S. adult obesity fell from 39.9% in 2022 to 36.4% this year, alongside a roughly tenfold increase in GLP-1 use since 2022; some treatments that cost over $1,000 monthly last year are now available for as little as $149. The commentary argues that time-limited patents enabled GLP-1 drug development and rival innovation, while competition is lowering prices; it notes generic versions in India cost less than $14 monthly after patents expired there. U.S. patents on blockbuster drugs such as Wegovy are expected to expire in the early 2030s, and the article highlights potential health-system savings against estimated annual costs of $173 billion for obesity and $413 billion for diabetes.

Analysis

The investment question is not whether GLP-1 use can expand, but whether patient growth outruns lower net prices, discontinuation, and payer restrictions. That trade-off can support substantial category growth without equivalent growth in manufacturer revenue or profit. The article’s affordability narrative therefore is not, by itself, a bullish earnings signal for Novo Nordisk or Eli Lilly; verify realized net pricing, supply, persistence, and coverage before extrapolating uptake.

Payers and employers could capture downstream savings over time, but the near-term budget impact is concentrated in drug spending while avoided complications accrue later and may benefit a different insurer. This timing mismatch can constrain coverage even if long-run health economics are favorable. Food, beverage, and other consumer businesses potentially exposed to lower consumption are a distant, noisy second-order effect—not a clean hedge against drugmakers.

The contrarian risk to the article’s thesis is that competition may lower prices faster than it expands treated populations, while patent durability, regulatory access, and manufacturing capacity determine who captures value. Lower-cost versions abroad do not establish the timing or economics of US generic substitution. Near term, monitor pricing, access, and prescribing data; over 1–3 months, payer decisions and company updates matter more than broad social-benefit claims. Over 6–18 months, differentiated efficacy, tolerability, and adherence may decide share. A reported obesity decline alone is not proof that drug use caused a durable population-level trend.

Key Decisions for Investors

• Do not trade the obesity-prevalence narrative as a standalone catalyst. Before taking directional exposure to Novo Nordisk or Eli Lilly, verify net price, prescription growth, treatment persistence, supply, and coverage; patient counts alone can mislead.
• Keep a relative-value comparison between Novo Nordisk and Eli Lilly on watch rather than initiating a pair trade without current valuation and product-level data. A potential long/short should depend on evidence that one company can sustain better net revenue growth through price competition—not merely on headline uptake.
• Track payer coverage and out-of-pocket affordability as near-term falsifiers: tightening access or faster-than-expected net-price erosion would undermine the volume-growth thesis; broader coverage alongside resilient realized pricing would strengthen it.
• Treat early-2030s patent expiry as a long-dated scenario, not an immediate generic catalyst. Verify relevant US patent claims, litigation, regulatory pathways, and product-specific exclusivity before assigning a generic-entry date or valuing a cliff.